ZTS Stock Recent News

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Phibro Animal Health's acquisition of Zoetis' medicated feed additive business has driven significant momentum and improved financial performance. Organic growth and margin expansion is seen across all segments, not just from the Zoetis deal, signaling a real operational turnaround. Despite a 50% share price rally, the stock remains attractively valued at a low double-digit earnings multiple, with manageable leverage.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).

Zoetis (ZTS) closed at $155.06 in the latest trading session, marking a -4.09% move from the prior day.

The Merck rival faces intense competition that could limit multiple expansion, Stifel analysts say.

U.S. equities were higher at midday as President Donald Trump again called on Federal Reserve Chair Jerome Powell to cut interest rates ahead of today's Fed decision. The Dow Jones Industrial Average, S&P 500, and Nasdaq all gained.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zoetis (ZTS) reached $168.82 at the closing of the latest trading day, reflecting a +1.5% change compared to its last close.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over time, will reward investors if you wait long enough.